This “Tau Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Tau Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Tau Inhibitors Understanding
Microtubule-associated protein tau is characterized by the fact that it is an intrinsically disordered protein due to its lack of a stable conformation and high flexibility. Intracellular inclusions of fibrillar forms of tau with a β-sheet structure accumulate in the brain of patients with Alzheimer's disease and other tauopathies. Accordingly, detachment of tau from microtubules and transition of tau from a disordered state to an abnormally aggregated state are essential events preceding the onset of tau-related diseases. Early anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy. Most of the tau-targeting approaches that are currently in clinical trials are immunotherapies. Tau is likely to be a better target than Aβ once cognitive deficits manifest, because the tau burden correlates better with clinical impairments than does the Aβ burden.
Tau Inhibitors - Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tau Inhibitors pipeline landscape is provided which includes the disease overview and Tau Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Tau Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tau Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Tau Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tau Inhibitors Emerging Drugs
TRx0237: TauRx Therapeutics
TRx0237 (LMTX) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. It is a replacement formulation for Rember, the first company's first proprietary formulation of methylthioninium chloride (MTC). TRx0237 and Rember share the same mode of action, but TRx0237 has been designed as a stabilized, reduced form of MTC to improve the drug's absorption, bioavailability, and tolerability.
IONIS-MAPTRx: Ionis Pharmaceuticals
IONIS-MAPTRx, also known as BIIB080, is an investigational antisense medicine designed to selectively reduce production of the tau protein in the brain. Microtubule-associated protein tau (MAPT) or tau, is thought to be a contributor or cause of certain neurodegenerative diseases, known as tauopathies,that are characterized by the deposition of abnormal tau protein in neurons and glia in the brain. These disorders include Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and some forms of frontotemporal degeneration (FTD). It is being developed in collaboration with Biogen for the treatment of Alzheimer's disease and frontotemporal degeneration.
This segment of the report provides insights about the different Tau Inhibitors drugs segregated based on following parameters that define the scope of the report.
There are approx. 25+ key companies which are developing the therapies for Tau Inhibitors. The companies which have their Tau Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, TauRx Therapeutics.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Tau Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau Inhibitors drugs.
Research Programme: gene therapies
Geography Covered
- Global coverage
Tau Inhibitors Understanding
Tau Inhibitors: Overview
Microtubule-associated protein tau is characterized by the fact that it is an intrinsically disordered protein due to its lack of a stable conformation and high flexibility. Intracellular inclusions of fibrillar forms of tau with a β-sheet structure accumulate in the brain of patients with Alzheimer's disease and other tauopathies. Accordingly, detachment of tau from microtubules and transition of tau from a disordered state to an abnormally aggregated state are essential events preceding the onset of tau-related diseases. Early anti-tau therapies were based mainly on inhibition of kinases or tau aggregation, or on stabilization of microtubules, but most of these approaches have been discontinued because of toxicity and/or lack of efficacy. Most of the tau-targeting approaches that are currently in clinical trials are immunotherapies. Tau is likely to be a better target than Aβ once cognitive deficits manifest, because the tau burden correlates better with clinical impairments than does the Aβ burden.
Tau Inhibitors - Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tau Inhibitors pipeline landscape is provided which includes the disease overview and Tau Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Tau Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tau Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Tau Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Tau Inhibitors.
Tau Inhibitors Emerging Drugs Chapters
This segment of the Tau Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tau Inhibitors Emerging Drugs
TRx0237: TauRx Therapeutics
TRx0237 (LMTX) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. It is a replacement formulation for Rember, the first company's first proprietary formulation of methylthioninium chloride (MTC). TRx0237 and Rember share the same mode of action, but TRx0237 has been designed as a stabilized, reduced form of MTC to improve the drug's absorption, bioavailability, and tolerability.
IONIS-MAPTRx: Ionis Pharmaceuticals
IONIS-MAPTRx, also known as BIIB080, is an investigational antisense medicine designed to selectively reduce production of the tau protein in the brain. Microtubule-associated protein tau (MAPT) or tau, is thought to be a contributor or cause of certain neurodegenerative diseases, known as tauopathies,that are characterized by the deposition of abnormal tau protein in neurons and glia in the brain. These disorders include Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and some forms of frontotemporal degeneration (FTD). It is being developed in collaboration with Biogen for the treatment of Alzheimer's disease and frontotemporal degeneration.
Tau Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Tau Inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players in Tau Inhibitors
There are approx. 25+ key companies which are developing the therapies for Tau Inhibitors. The companies which have their Tau Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, TauRx Therapeutics.
Phases
This report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Tau Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Tau Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau Inhibitors drugs.
Tau Inhibitors Report Insights
- Tau Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Tau Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tau Inhibitors drugs?
- How many Tau Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tau Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tau Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tau Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- TauRx Therapeutics
- Ionis Pharmaceuticals
- UCB Biopharma
- Alterity Therapeutics
- Pinteon Therapeutics
- Voyager Therapeutics
- Oligomerix
Key Products
- TRx0237
- IONIS-MAPTRx
- Bepranemab
- ATH 434
- PNT-001
Research Programme: gene therapies
- OLX-07010
Table of Contents
IntroductionExecutive Summary
Tau Inhibitors: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
TRx0237: TauRx Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
IONIS-MAPTRx: Ionis Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
ATH 434: Alterity Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Tau Inhibitors Key Companies
Tau Inhibitors Key Products
Tau Inhibitors- Unmet Needs
Tau Inhibitors- Market Drivers and Barriers
AppendixList of Tables
Table 1 Total Products for Tau Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Tau Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- TauRx Therapeutics
- Ionis Pharmaceuticals
- UCB Biopharma
- Alterity Therapeutics
- Pinteon Therapeutics
- Voyager Therapeutics
- Oligomerix
